A kit containing a crystalline form of a quinazoline compound. More particularly, the crystalline form is derived from the compound of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one. Also disclosed is a method of treating cancers with the crystalline form or a kit thereof.

A kit containing a crystalline form of a quinazoline compound. More particularly, the crystalline form is derived from the compound of 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one. Also disclosed is a method of treating cancers with the crystalline form or a kit thereof.

The present invention provides compositions and methods of for improving the Health-Related Quality of Life of a subject suffering from rheumatoid arthritis, comprising administering to the subject an effective amount of sarilumab.

The present invention provides compositions and methods of for improving the Health-Related Quality of Life of a subject suffering from rheumatoid arthritis, comprising administering to the subject an effective amount of sarilumab.

Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.

Simultaneous inhibition of the aryl hydrocarbon receptor (AhR) and SRC abolishing androgen receptor (AR) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (AhR) antagonist and an SRC inhibitor. In one embodiment, the therapeutic composition further comprises a pharmaceutical excipient. In one embodiment, the AhR antagonist is CH223191 and the SRC inhibitor is PP2 and the therapeutic composition further comprises a pharmaceutical excipient. Methods of using the therapeutic composition to treat prostate cancer or to inhibit prostate cancer cells are also disclosed.

This invention disclosed a new use of optically pure R-enantiomer of adrenergic β2 agonists including R-salbutamol, R-terbutaline, R-clenbuterol and R-bambuterol for treatment of inflammatory bowel disease and its extra intestinal manifestations including skin diseases.

This invention disclosed a new use of optically pure R-enantiomer of adrenergic β2 agonists including R-salbutamol, R-terbutaline, R-clenbuterol and R-bambuterol for treatment of inflammatory bowel disease and its extra intestinal manifestations including skin diseases.

The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed.

The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed.